首页> 外国专利> Oligorribonucleotidos of reverse structures linked by amide groups, Intermediate Compounds, Pharmaceutical composition containing them.A process for preparing the pharmaceutical Composition and the group of these compounds as Drugs.

Oligorribonucleotidos of reverse structures linked by amide groups, Intermediate Compounds, Pharmaceutical composition containing them.A process for preparing the pharmaceutical Composition and the group of these compounds as Drugs.

机译：通过酰胺基团连接的具有反向结构的寡核糖核苷酸，中间化合物，包含它们的药物组合物。制备药物组合物的方法以及这些化合物作为药物的组。

页面导航

摘要
著录项
相似文献

摘要

The reverse direction nucleon oligonucleotide structure is composed of non parent-child binding, as shown in Formula 1:Among them, R1 is h, the tar of one carbon atom, the acidity of one to eighteen carbon atoms, or the lower hydrogen peroxide group; R2 is h, aralquilo or tar of one to four decaying atoms; a is the radical substance of optional nucleon group selected from adenosine group and properly protected, 1. Guanina, timina and uracilo; X is h, or1, nhr2 or nh-acil; it is or2 or nhr2; K is the amount of 0-25; its salts; intermediate compounds only used for the production of oligonucleotide, including drug components containing these nucleon oligonucleotide;A process for developing the drug's components, as well as the use of nuclear oligonucleotides to reduce target protein production in cells.

机译：反向核子寡核苷酸结构由非亲子结合组成，如式1所示：其中R1为h，一个碳原子的tar，一个至18个碳原子的酸度或较低的过氧化氢基团; R 2为h，alalquilo或具有1-4个衰变原子的焦油; a。鸟嘌呤，蒂米纳和尿嘧啶; a为选自腺苷基团并经过适当保护的任选核子基团的自由基物质。 X是h或1，nhr2或nh-acil;它是or2或nhr2; K为0-25;其盐;仅用于生产寡核苷酸的中间体化合物，包括包含这些核苷寡核苷酸的药物成分;开发药物成分的过程以及使用核寡核苷酸减少细胞中靶蛋白的产生。

著录项

公开/公告号AR002003A1

专利类型
公开/公告日1998-01-07

原文格式PDF
申请/专利权人 F. HOFFMANN-LA ROCHE AG.;
展开▼

申请/专利号AR19950100349
发明设计人
展开▼

申请日1995-11-28
分类号C07H21/02;C07H19/073;C07H19/173;A61K31/70;
国家 AR
入库时间 2022-08-22 02:58:51

相似文献

专利
外文文献
中文文献